128 related articles for article (PubMed ID: 37944991)
21. Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia.
Yang S; Ma R; Yuan X; Jiang L; Shi J; Yang J; Lei P; Zang Y; Chen X; Zhang Y; Liu Z; Guo J; Zhang L; Zhu X; Zhu Z
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e382-e391. PubMed ID: 32336675
[TBL] [Abstract][Full Text] [Related]
22. Toward Candidate Proteomic Biomarkers in Clinical Monitoring of Acute Promyelocytic Leukemia Treatment with Arsenic Trioxide.
Cao F; Li X; Yang Y; Fang H; Qu H; Chang N; Ma Q; Cao W; Zhou J; Wang W
OMICS; 2019 Feb; 23(2):119-130. PubMed ID: 30767729
[TBL] [Abstract][Full Text] [Related]
23. UK Experience of an Alternative ATO Dosing Regimen in APL.
Russell N; Dillon R
Front Oncol; 2020; 10():594129. PubMed ID: 33262951
[TBL] [Abstract][Full Text] [Related]
24. Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.
Kutny MA; Alonzo TA; Gerbing RB; Wang YC; Raimondi SC; Hirsch BA; Fu CH; Meshinchi S; Gamis AS; Feusner JH; Gregory JJ
J Clin Oncol; 2017 Sep; 35(26):3021-3029. PubMed ID: 28767288
[TBL] [Abstract][Full Text] [Related]
25. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
26. Aquaporin 9, a promising predictor for the cytocidal effects of arsenic trioxide in acute promyelocytic leukemia cell lines and primary blasts.
Iriyama N; Yuan B; Yoshino Y; Hatta Y; Horikoshi A; Aizawa S; Takeuchi J; Toyoda H
Oncol Rep; 2013 Jun; 29(6):2362-8. PubMed ID: 23563754
[TBL] [Abstract][Full Text] [Related]
27. The Combination of Gefitinib With ATRA and ATO Induces Myeloid Differentiation in Acute Promyelocytic Leukemia Resistant Cells.
de Almeida LY; Pereira-Martins DA; Weinhäuser I; Ortiz C; Cândido LA; Lange AP; De Abreu NF; Mendonza SES; de Deus Wagatsuma VM; Do Nascimento MC; Paiva HH; Alves-Paiva RM; Bonaldo CCOM; Nascimento DC; Alves-Filho JC; Scheucher PS; Lima ASG; Schuringa JJ; Ammantuna E; Ottone T; Noguera NI; Araujo CL; Rego EM
Front Oncol; 2021; 11():686445. PubMed ID: 34650910
[TBL] [Abstract][Full Text] [Related]
28. Oral arsenic trioxide for treating acute promyelocytic leukaemia: Implications for its worldwide epidemiology and beyond.
Kumana CR; Kwong YL; Gill H
Front Oncol; 2022; 12():1026478. PubMed ID: 36518307
[TBL] [Abstract][Full Text] [Related]
29. Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial.
Kutny MA; Alonzo TA; Abla O; Rajpurkar M; Gerbing RB; Wang YC; Hirsch BA; Raimondi S; Kahwash S; Hardy KK; Hardy S; Meshinchi S; Gamis AS; Kolb EA; Feusner JH; Gregory J
JAMA Oncol; 2022 Jan; 8(1):79-87. PubMed ID: 34762093
[TBL] [Abstract][Full Text] [Related]
30. Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity.
Dbaibo GS; Kfoury Y; Darwiche N; Panjarian S; Kozhaya L; Nasr R; Abdallah M; Hermine O; El-Sabban M; de Thé H; Bazarbachi A
Haematologica; 2007 Jun; 92(6):753-62. PubMed ID: 17550847
[TBL] [Abstract][Full Text] [Related]
31. Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
Firkin F; Roncolato F; Ho WK
Eur J Haematol; 2015 Oct; 95(4):331-5. PubMed ID: 25600167
[TBL] [Abstract][Full Text] [Related]
32. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
33. [Comparison of Curative Effect between Fu Fang Huang Dai Pian and Arsenic Trioxide in Treatment of 45 Patients with Acute Promyelocytic Leukaemia].
Wang J; Huang JB; Liu ZL; Zhang BH; Xu HG; Xue HM; Chen C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1605-1610. PubMed ID: 29262883
[TBL] [Abstract][Full Text] [Related]
34. Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy.
Li T; Ma R; Zhang Y; Mo H; Yang X; Hu S; Wang L; Novakovic VA; Chen H; Kou J; Bi Y; Yu B; Fang S; Wang J; Zhou J; Shi J
Cell Death Dis; 2018 Jan; 9(2):75. PubMed ID: 29362482
[TBL] [Abstract][Full Text] [Related]
35. Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy.
Leech M; Morris L; Stewart M; Smith BD; Bashey A; Holland K; Solomon S; Zhang X; Carraway HE; Pratz K; Gore SD; Zeidan AM
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):292-7. PubMed ID: 25499624
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience.
Autore F; Chiusolo P; Sorà F; Giammarco S; Laurenti L; Innocenti I; Metafuni E; Piccirillo N; Pagano L; Sica S
Front Oncol; 2021; 11():614721. PubMed ID: 34336637
[TBL] [Abstract][Full Text] [Related]
37. G-CSF upregulates the expression of aquaporin-9 through CEBPB to enhance the cytotoxic activity of arsenic trioxide to acute myeloid leukemia cells.
Fu W; Zhu G; Xu L; Liu J; Han X; Wang J; Wang X; Hou J; Zhao H; Zhong H
Cancer Cell Int; 2022 May; 22(1):195. PubMed ID: 35590355
[TBL] [Abstract][Full Text] [Related]
38. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.
Soignet SL; Frankel SR; Douer D; Tallman MS; Kantarjian H; Calleja E; Stone RM; Kalaycio M; Scheinberg DA; Steinherz P; Sievers EL; Coutré S; Dahlberg S; Ellison R; Warrell RP
J Clin Oncol; 2001 Sep; 19(18):3852-60. PubMed ID: 11559723
[TBL] [Abstract][Full Text] [Related]
39. Melatonin enhances arsenic trioxide-induced cytotoxicity by modulating autophagy in an acute promyelocytic leukemia cell line.
Wei X; Pu X; Yang S; Meng X; Chen X; Zhang Z; Sheng X; Xiang D; Zhang Y
Transl Cancer Res; 2019 Sep; 8(5):2079-2088. PubMed ID: 35116957
[TBL] [Abstract][Full Text] [Related]
40. Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial).
Chen L; Zhu HM; Li Y; Liu QF; Hu Y; Zhou JF; Jin J; Hu JD; Liu T; Wu DP; Chen JP; Lai YR; Wang JX; Li J; Li JY; Du X; Wang X; Yang MZ; Yan JS; Ouyang GF; Liu L; Hou M; Huang XJ; Yan XJ; Xu D; Li WM; Li DJ; Lou YJ; Wu ZJ; Niu T; Wang Y; Li XY; You JH; Zhao HJ; Chen Y; Shen Y; Chen QS; Chen Y; Li J; Wang BS; Zhao WL; Mi JQ; Wang KK; Hu J; Chen Z; Chen SJ; Li JM
Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33495363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
